Ligand Pharmaceuticals (LGND) Cash from Operations (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Cash from Operations of 48691000.0 for Q1 2026, up 6.05% sequentially from 45915000.0 in Q4 2025, and up 291.36% YoY from 12441555.07 in Q1 2025.
Ligand Pharmaceuticals (LGND) Cash from Operations (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 48691000.0 in Q1 2026.
- Quarterly Cash from Operations rose 291.36% year-over-year to 48691000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 123495000.0 (up 133.58% YoY) and the FY2025 annual result came in at 49359000.0, down 49.14% from the prior year.
- Cash from Operations rose to 48691000.0 in Q1 2026 per LGND's latest filing, from 45915000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 53472000.0 in Q4 2022 and troughed at 25445000.0 in Q1 2025.
- A 5-year average of 22501411.76 and a median of 18732000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations soared 16336.59% in 2024, then slumped 235.84% in 2025.
- Over 5 years, Cash from Operations stood at 53472000.0 in 2022, then slumped by 84.92% to 8065000.0 in 2023, then surged by 253.02% to 28471000.0 in 2024, then jumped by 61.27% to 45915000.0 in 2025, then increased by 6.05% to 48691000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 48691000.0, 45915000.0, and 13090000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 24.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.02 Mn |
| Jun 30, 2026 | 24.02 Mn |
| Mar 31, 2026 | 48.69 Mn |
| Mar 31, 2026 | 48.69 Mn |
| Dec 31, 2025 | 45.92 Mn |
| Dec 31, 2025 | 45.92 Mn |
| Sep 30, 2025 | 13.09 Mn |
| Sep 30, 2025 | 13.09 Mn |
| Jun 30, 2025 | 15.80 Mn |
| Jun 30, 2025 | 15.80 Mn |
| Mar 31, 2025 | -25.45 Mn |
| Mar 31, 2025 | -25.45 Mn |
| Dec 31, 2024 | 28.47 Mn |
| Dec 31, 2024 | 28.47 Mn |
| Sep 30, 2024 | 36.53 Mn |
| Sep 30, 2024 | 36.53 Mn |
| Jun 30, 2024 | 13.31 Mn |
| Jun 30, 2024 | 13.31 Mn |
| Mar 31, 2024 | 18.73 Mn |
| Mar 31, 2024 | 18.73 Mn |